GleamWall
中文EN

ZBIO Zenas BioPharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1953926 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-185.3%
TTM EPS YoY-173.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-265.1%
ROA-108.7%
ROIC (approx.)-441.5%
Asset turnover—

Leverage & solvency

Liabilities / assets68.6%
Debt / equity0.00x
Current ratio9.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-60.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.00M$1.00M—$0$0$0$10.00M$5.00M
R&D expense$58.47M$62.91M$60.44M$55.72M$34.40M$43.03M$34.91M$49.16M
SG&A expense$27.43M$15.75M$16.91M$15.59M$13.18M$12.14M$12.41M$11.47M
Operating income-$103.41M-$107.66M-$77.35M-$237.98M-$52.58M-$55.16M-$37.33M-$55.62M
Interest expense$2.06M$1.72M$368,000—————
Pretax income-$108.87M-$111.34M-$80.99M-$240.34M-$51.50M-$52.20M-$33.78M-$52.17M
Income tax$49,000$114,000—$106,000$0$20,000-$205,000—
Net income-$108.92M-$111.46M-$80.99M-$240.44M-$51.50M-$52.22M-$33.57M-$52.60M
EBITDA-$103.41M-$107.66M-$77.34M-$237.97M-$52.57M-$55.15M-$37.31M-$55.59M
EPS (basic)-1.65-1.77-1.46—-1.22-1.25-0.80—
EPS (diluted)-1.65-1.77-1.46—-1.22-1.25-0.80—
Weighted avg. shares (diluted)66.15M63.11M55.62M—42.16M41.87M41.80M—
Balance sheet
Cash & equivalents$177.78M$196.58M$500.22M$110.64M$115.56M$44.01M$196.55M$319.83M
Short-term investments$407.53M$446.55M$216.98M$232.55M$175.32M$229.27M$115.83M$31.02M
Current assets$603.45M$653.79M$730.16M$351.17M$296.64M$278.60M$317.81M$355.92M
PP&E, net$19,000$23,000$28,000$34,000$50,000$61,000$72,000$185,000
Total assets$675.22M$701.69M$747.68M$383.64M$322.02M$293.08M$333.77M$369.97M
Current liabilities$64.04M$65.82M$61.16M$62.65M$52.42M$53.24M$49.13M$57.29M
Long-term debt———$78.64M$72.99M———
Total debt———$78.64M$72.99M———
Total liabilities$462.91M$454.59M$411.85M$141.50M$125.59M$53.46M$49.45M$57.51M
Shareholders' equity$212.31M$247.10M$335.83M$242.14M$196.43M$239.63M$284.32M$312.46M
Net debt———-$32.01M-$42.58M———
Shares outstanding67.80M63.33M62.38M54.49M42.21M42.09M41.82M41.79M
Cash flow statement
Operating cash flow-$57.98M-$57.24M-$75.20M-$52.41M-$41.12M-$41.74M-$37.05M-$38.55M
Capital expenditure$1,000$0$2,000$0$0$0$18,000$74,000
Free cash flow-$57.98M-$57.24M-$75.20M-$52.41M-$41.12M-$41.74M-$37.07M-$38.63M
Investing cash flow-$19.21M-$287.70M$31.61M-$93.36M$40.04M-$112.29M-$86.27M-$3.73M
Financing cash flow$57.21M$42.06M$433.48M$140.84M$72.62M$1.72M$99,000$1.85M
Depreciation & amortization$4,000$4,000$6,000$10,000$11,000$12,000$23,000$33,000
Stock-based compensation$17.28M$8.62M$9.20M$7.58M$7.34M$6.04M$5.39M$5.50M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.